dexamethasone,lenalidomide,bortezomib
takeda
['multiple myeloma', 'determination']
plenary abstract 4: dr. richardson, determination trial: rvd +/- asct and len maintenance to progression for multiple myeloma. median pfs was 46.2 (no asct) vs. 67.6 mos (with asct) (hr 1.53; 95% ci, 1.23 1.91; p &lt; .0001). #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.